Is it important to measure or reduce C-reactive protein in people at risk of cardiovascular disease?

European Heart Journal

Volumn 33, Issue 18, 2012, Pages 2258-2264

  Hingorani, Aroon D ^a   Sofat, Reecha ^a   Morris, Richard W ^b   Whincup, Peter ^c   Lowe, Gordon D ^d   Mindell, Jennifer ^a   Sattar, Naveed ^d   Casas, Juan P ^a,e   Shah, Tina ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^d UNIVERSITY OF GLASGOW   (United Kingdom)

^e LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL; PLACEBO; PRAVASTATIN; ROSUVASTATIN;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COST EFFECTIVENESS ANALYSIS; GENETIC ASSOCIATION; HIGH RISK POPULATION; HUMAN; ISCHEMIC HEART DISEASE; NOTE; OBSERVATIONAL STUDY; PREDICTION; PRIMARY PREVENTION; PRIORITY JOURNAL; PROTEIN TARGETING; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; REGRESSION ANALYSIS; RISK ASSESSMENT; RISK FACTORS;

EID: 84866420405     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehs168     Document Type: Note

References (37)

1. The Emerging Risk Factors Collaboration. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 2010;375:132-140.
2. Venugopal SK, Devaraj S, Jialal I. Effect of C-reactive protein on vascular cells: evidence for a proinflammatory, proatherogenic role. Curr Opin Nephrol Hypertens 2005;14:33-37. (Pubitemid 40110697)
3. Mora S, Ridker PM. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)\Can C-reactive protein be used to target statin therapy in primary prevention? Am J Cardiol 2006;97(2, Suppl. 1):33-41.
4. Ridker PM, Danielson E, Fonseca FAH, Genest J, Gotto AM Jr, Kastelein JJP, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ, the JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-2207.
5. Young I, Rifai N. High-sensitivity C-reactive protein and cardiovascular disease. Clin Chem 2009;55:201-202.
6. Genest J, McPherson R, Frohlich J, Anderson T, Campbell N, Carpentier A, Couture P, Dufour R, Fodor G, Francis GA, Grover S, Gupta M, Hegele RA, Lau DC, Leiter L, Lewis GF, Lonn E, Mancini GB, Ng D, Pearson GJ, Sniderman A, Stone JA, Ur E. 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult\2009 recommendations. Can J Cardiol 2009;25: 567-579.
7. Greenland P, Alpert JS, Beller GA, Benjamin EJ, Budoff MJ, Fayad ZA, Foster E, Hlatky MA, Hodgson JM, Kushner FG, Lauer MS, Shaw LJ, Smith SC Jr, Taylor AJ, Weintraub WS, Wenger NK. 2010 ACCF/AHA Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults: Executive Summary: a Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration with the American Society of Echocardiography, American Society of Nuclear Cardiology, Society of Atherosclerosis Imaging and Prevention, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance. J Am Coll Cardiol 2010;56:2182-2199.
8. Graham I. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Atherosclerosis 2007;194:1-45. (Pubitemid 47470068)
9. Ridker PM, Glynn RJ. JUPITER, rosuvastatin, and the European Medicines Agency. Lancet 2010;375:2071.
10. Wald NJ, Morris JK, Rish S. The efficacy of combining several risk factors as a screening test. J Med Screen 2005;12:197-201. (Pubitemid 43843295)
11. Shah T, Casas JP, Cooper JA, Tzoulaki I, Sofat R, McCormack V, Smeeth L, Deanfield JE, Lowe GD, Rumley A, Fowkes FG, Humphries SE, Hingorani AD. Critical appraisal of CRP measurement for the prediction of coronary heart disease events: new data and systematic review of 31 prospective cohorts. Int J Epidemiol 2009;38:217-231.
12. Rose G. Sick individuals and sick populations. Int J Epidemiol 1985;14:32-38. (Pubitemid 15109489)
13. The Emerging Risk Factors Collaboration. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009;302:1993-2000.
14. Wald NJ, Hackshaw AK, Frost CD. When can a risk factor be used as a worthwhile screening test? Br Med J 1999;319:1562-1565.
15. Wald DS, Kasturiratne A, Bestwick JP. The value of C-reactive protein in screening for future coronary heart disease events. J Med Screen 2009;16:212-214.
16. Shah T, Newcombe P, Smeeth L, Addo J, Casas JP, Whittaker J, Miller MA, Tinworth L, Jeffery S, Strazzullo P, Cappuccio FP, Hingorani AD. Ancestry as a determinant of mean population C-reactive protein values: implications for cardiovascular risk prediction. Circ Cardiovasc Genet 2010;3:436-444.
17. Ridker PM, Buring JE, Rifai N, Cook NR. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds risk score. JAMA 2007;297:611-619.
18. Kinlay S. Low-density lipoprotein-dependent and-independent effects of cholesterol-lowering therapies on C-reactive protein: a meta-analysis. J Am Coll Cardiol 2007;49:2003-2009. (Pubitemid 46734641)
19. Nissen SE, Tuzcu EM, Schoenhagen P, Crowe T, Sasiela WJ, Tsai J, Orazem J, Magorien RD, O'Shaughnessy C, Ganz P, the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) Investigators. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 2005;352: 29-38.
20. Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, Pfeffer MA, Braunwald E, the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005;352:20-28.
21. van den Berg CW, Taylor KE, Lang D. C-reactive protein-induced in vitro vasor-elaxation is an artefact caused by the presence of sodium azide in commercial preparations. Arterioscler Thromb Vasc Biol 2004;24:e168-e171.
22. Pepys MB, Hawkins PN, Kahan MC, Tennent GA, Gallimore JR, Graham D, Sabin CA, Zychlinsky A, de Diego J. Proinflammatory effects of bacterial recom-binant human C-reactive protein are caused by contamination with bacterial products, not by C-reactive protein itself. Circ Res 2005;97:e97-e103.
23. Tennent GA, Hutchinson WL, Kahan MC, Hirschfield GM, Gallimore JR, Lewin J, Sabin CA, Dhillon AP, Pepys MB. Transgenic human CRP is not pro-atherogenic, pro-atherothrombotic or pro-inflammatory in apoE2/2 mice. Atherosclerosis 2008;196:248-255.
24. Casas JP, Shah T, Cooper J, Hawe E, McMahon AD, Gaffney D, Packard CJ, O'Reilly DS, Juhan-Vague I, Yudkin JS, Tremoli E, Margaglione M, Di Minno G, Hamsten A, Kooistra T, Stephens JW, Hurel SJ, Livingstone S, Colhoun HM, Miller GJ, Bautista LE, Meade T, Sattar N, Humphries SE, Hingorani AD. Insight into the nature of the CRP-coronary event association using Mendelian randomization. Int J Epidemiol 2006;35:922-931. (Pubitemid 44540742)
25. Zacho J, Tybjaerg-Hansen A, Jensen JS, Grande P, Sillesen H, Nordestgaard BG. Genetically elevated C-reactive protein and ischemic vascular disease. N Engl J Med 2008;359:1897-1908.
26. CRP CHD Genetics Collaboration. Association between C reactive protein and coronary heart disease: Mendelian randomisation analysis based on individual participant data. Br Med J 2011;342:d548.
27. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R, Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-1278.
28. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipo-protein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. Br Med J 2003;326:1423.
29. Heart Protection Study Collaborative Group. C-reactive protein concentration and the vascular benefits of statin therapy: an analysis of 20,536 patients in the Heart Protection Study. Lancet 2011;377:469-476.
30. Sever PS, Poulter NR, Chang CL, Hingorani A, Thom SA, Hughes AD, Welsh P, Sattar N. Evaluation of C-reactive protein prior to and on-treatment as a predictor of benefit from atorvastatin: observations from the Anglo-Scandinavian Cardiac Outcomes Trial. Eur Heart J 2012;33:486-494.
31. Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles JS, Gotto AM Jr, Air Force/Texas Coronary Atherosclerosis Prevention Study I. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001;344:1959-1965. (Pubitemid 32568149)
32. Sattar N, Murray HM, McConnachie A, Blauw GJ, Bollen ELEM, Buckley BM, Cobbe SM, Ford I, Gaw A, Hyland M, Jukema JW, Kamper AM, Macfarlane PW, Murphy MB, Packard CJ, Perry IJ, Stott DJ, Sweeney BJ, Twomey C, Westendorp RGJ, Shepherd J, for the PROSPER Study Group. C-reactive protein and prediction of coronary heart disease and global vascular events in the prospective study of pravastatin in the elderly at risk (PROSPER). Circulation 2007;115:981-989. (Pubitemid 46328291)
33. Ridker PM, Fonseca FAH, Genest J, Gotto AM, Kastelein JJP, Khurmi NS, Koenig W, Libby P, Lorenzatti AJ, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ. Baseline characteristics of participants in the JUPITER trial, a randomized placebo-controlled primary prevention trial of statin therapy among individuals with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein. Am J Cardiol 2007;100:1659-1664. (Pubitemid 350122337)
34. Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010;376:1670-1681.
35. Ridker PM, MacFadyen J, Libby P, Glynn RJ. Relation of baseline high-sensitivity C-reactive protein level to cardiovascular outcomes with rosuvastatin in the Justification for Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvas-tatin (JUPITER). Am J Cardiol 2010;106:204-209.
36. Bassler D, Briel M, Montori VM, Lane M, Glasziou P, Zhou Q, Heels-Ansdell D, Walter SD, Guyatt GH, the STOPIT-. Stopping randomized trials early for benefit and estimation of treatment effects: systematic review and meta-regression analysis. JAMA 2010;303:1180-1187.
37. Wald NJ, Simmonds M, Morris JK. Screening for future cardiovascular disease using age alone compared with multiple risk factors and age. PLoS One 2011;6: e18742.